Publication | Closed Access

Poor oral bioavailability of a promising anticancer agent andrographolide is due to extensive metabolism and efflux by P‐glycoprotein

Pharmaceutical ScienceMedicinePharmacologyPharmacotherapyAnti-cancer AgentPoor Oral BioavailabilityExtensive MetabolismCancer MetabolismRadiation OncologyCancer ResearchGlycosylation